Salarius Pharmaceuticals Inc expected to post a loss of 8  cents a share - Earnings Preview

Decoy Therapeutics

08/03/2022 21:07

* Salarius Pharmaceuticals Inc  SLRX.OQ   SLRX.O  is
expected
to show a fall in quarterly revenue when it reports  results on
March 10. 
    * The Houston Texas-based  company is expected to report  a
70.7% decrease in revenue to $433.33 thousand from $1.48 million
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Salarius
Pharmaceuticals
Inc is for a loss of 8 cents per share. For the same quarter
last year, the company reported a loss of 10 cents per share.
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Salarius
Pharmaceuticals Inc is $5​, above​ its last closing price
of $0.37. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.07       -0.06      -0.08     Missed  -23.1
 Jun. 30 2021  -0.06       -0.06      -0.07     Missed  -23.5
 Mar. 31 2021  -0.06       -0.05      -0.06     Missed  -9.1​
 Dec. 31 2020              -0.11      -0.10     Beat    9.1
 ​​Sep.        -0.11       -0.10      -0.10     Met     4.8
 30 2020                                                
 Jun. 30 2020  -0.16       -0.16      -0.13     Beat    21.2​
 Mar. 31 2020  -0.44       -0.44      -0.22     Beat    50
                                      -0.44             
 This summary was machine generated March 8 at 21:07 GMT.  All
figures in US dollars  unless otherwise stated